License Agreements (Details)		1 Months Ended			3 Months Ended				6 Months Ended
	Mar. 03, 2022 USD ($) installment	Jun. 30, 2022 USD ($)	Apr. 30, 2022 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) installment item	Jun. 30, 2021 USD ($)	Jun. 29, 2022 USD ($)	Jun. 28, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)
License Agreements [Line Items]
Accrued milestone payment											$ 2,000,000.0	$ 3,000,000.0
Research and development expense, reduction							$ 1,000,000.0		$ 1,000,000.0
Daiichi Sankyo License Agreement
License Agreements [Line Items]
License agreement, effective date									Sep. 02, 2020
Upfront payment				$ 5,000,000.0
Sublicensable rights, number of families of patents | item									7
Number of clinical trials | item									3
Reimburse total	$ 2,000,000.0
Number of installments reimbursement paid | installment	4
Reimbursement paid in each installment	$ 500,000	$ 500,000	$ 500,000
Period of installment maturity date									Dec. 31, 2022
Other clinical trials payments							57,000		$ 87,000
Clinical trial payments								$ 0		$ 0
Clinical trial costs		1,000,000.0					1,000,000.0		1,000,000.0				$ 2,000,000.0
Maximum future milestone payments		223,500,000					223,500,000		223,500,000
Clinical trials reimbursement expense									2,000,000.0
Milestone fees		0					0	0	0	0				$ 5,500,000
Milestone payments														2,500,000
Accrued milestone payment														$ 3,000,000.0
Royalty payments									$ 0
Royalty obligation termination description									The royalty obligation terminates on a country-by-country and on a product-by-product basis on the later of: (i) loss of all market exclusivity for such Product in such country, (ii) the last-to-expire patent that covers the Licensed Compound or the Product in such country and (iii) twelve years from launch of the first Product sold by the Company in such country.
Cure period									90 days
Agreement termination written notice period									6 months
Daiichi Sankyo License Agreement | Forecast
License Agreements [Line Items]
Future reimbursement installment payable					$ 500,000	$ 500,000
Drexel License Agreement | Drexel University
License Agreements [Line Items]
Intellectual property license agreement date									Jul. 30, 2020
Intellectual property license agreement description									Pursuant to the Drexel License Agreement, Drexel granted to the Company (i) a worldwide, exclusive license to make and commercialize products under a single issued patent and two patent applications related to RAD52 inhibitors for the treatment of cancer (the “Patent Rights”) and (ii) a worldwide, nonexclusive license to make, use and commercialize certain technical information and know-how related to the Patent Rights. The license grant includes the right to sublicense after the first anniversary of the Effective Date, subject to express conditions set forth in the Drexel License Agreement.
Intellectual property license agreement period									5 years
One time non refundable initiation fee									$ 20,000
Number of equal instalments paid one time non refundable initiation fee | installment									4
One time non-refundable initiation fee paid in each installment									$ 5,000
Period of first instalment after effective date									10 days
Period of second instalment after effective date									6 months
Period of third instalment after effective date									12 months
Period of fourth instalment after effective date									18 months
Maximum future payments in addition to initiation fee		6,250,000					6,250,000		$ 6,250,000
Upper limit of minimum quarterly royalty payments		6,250					6,250		6,250
Annual license maintenance fee until first sale of first licensed product		$ 15,000					15,000		15,000
Payments for license agreements							$ 33,000	$ 0	$ 38,000	$ 19,000
Agreement period from first sale of first licensed product									10 years